<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="of the adults hospitalized for COVID-19 with underlying conditions in" exact="the USA," post="74.8% had chronic renal disease. Evidence synthesis Evidence is"/>
 <result pre="of the adults hospitalized for COVID-19 with underlying conditions in" exact="the USA," post="74.8% had chronic renal disease. 3 Evidence synthesis 3.1"/>
 <result pre="address some of these needs, several hospitals and clinics in" exact="the USA" post="have adopted a telehealth care delivery approach; however, such"/>
 <result pre="of the adults hospitalized for COVID-19 with underlying conditions in" exact="the USA," post="74.8% had chronic renal disease, but patients with chronic"/>
 <result pre="COVID-19 spread in hemodialysis (HD) centers [34], [35], [36]. In" exact="the USA" post="specifically, 0.5 million individuals receive dialysis treatment and constitute"/>
 <result pre="or die of acute renal failure [33]. Several studies in" exact="China" post="have tracked the development of AKI once admitted for"/>
 <result pre="frame [6], [25]. One study of 1099 cases from mainland" exact="China" post="showed that six (0.5%) COVID-19 patients developed AKI [5]."/>
 <result pre="evaluating the risk factors of developing severe COVID-19 infections. In" exact="the USA," post="nearly 60 000 individuals had RCC in 2018, although"/>
 <result pre="medicine. Recently, RCC-based liquid biopsy was validated and approved by" exact="the US" post="FDA for the prognosis and diagnosis of the disease"/>
 <result pre="was effective in the treatment of a COVID-19 patient in" exact="the USA" post="[75], [78]. Further research efforts focus on drugs that"/>
</results>
